HuGE Literature Finder
|
||
Records 1-100
|
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
British journal of clinical pharmacology 2019 Apr . Helin Tuukka A, Joutsi-Korhonen Lotta, Asmundela Heidi, Niemi Mikko, Orpana Arto, Lassila Riit |
|
Prosthetic valve thrombosis - association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes.
Medicine 2019 Feb 98 (6): e14365. Sr Kalpana, G Bharath, Jain Simran, Moorthy Nagaraja, Manjunath Satvic C, Christopher Ri |
|
Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Indian heart journal 2018 Dec 70 Suppl 3 S13-S19. Biswas Mansij, Bendkhale Shital R, Deshpande Siddharth P, Thaker Saket J, Kulkarni Dwarkanath V, Bhatia Shobna J, Rajadhyaksha Anjali G, Gogtay Nithya J, Thatte Urmila |
|
The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2018 Apr 34 (2): 328-336. Bedewy Ahmed M L, Showeta Salah, Mostafa Mostafa Hasan, Kandil Lamia Sae |
|
Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Vascular pharmacology 2018 Feb . Bryk Agata Hanna, Wypasek Ewa, Plens Krzysztof, Awsiuk Magdalena, Undas Anet |
|
Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
European journal of clinical pharmacology 2018 Feb . Ajmi Marwa, Omezzine Asma, Achour Slim, Amor Dorra, Hamdouni Haithem, Ismaïl Fatma Ben Fredj, Rejeb Nabila Ben, Kechrid Chedia Laouani, Boughzela Essia, Bouslama A |
|
VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.
Future cardiology 2018 Jan 14 (1): 15-26. Mili Fatima Donia, Allen Tenecia, Wadell Paula Weinstein, Hooper W Craig, Staercke Christine De, Bean Christopher J, Lally Cathy, Austin Harland, Wenger Nanette |
|
Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Genetic testing and molecular biomarkers 2017 Sep . Ju Shang, Gao Yu, Cao Xin, Zhang Xiao-Fu, Yan Cheng-Cheng, Liu Feng-To |
|
Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Journal of thrombosis and haemostasis : JTH 2017 Aug . Nagler M, Angelillo-Scherrer A, Méan M, Limacher A, Abbal C, Righini M, Beer J H, Osterwalder J, Frauchiger B, Aschwanden M, Matter C M, Kucher N, Cornuz J, Banyai M, Husmann M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky |
|
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2017 Apr . Park Yun Kyung, Lee Mi Ji, Kim Jae Ha, Lee Jin Soo, Park Rae Woong, Kim Gyeong-Moon, Chung Chin-Sang, Lee Kwang Ho, Kim June Soo, Lee Soo-Youn, Bang Oh You |
|
Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing 2017 Mar 35 (1): 27-30. Schapkaitz Elise, Sithole Johan |
|
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Journal of thrombosis and haemostasis : JTH 2017 Jan . Hernandez Wenndy, Gamazon Eric R, Aquino-Michaels Keston, Smithberger Erin, O'Brien Travis J, Harralson Arthur F, Tuck Matthew, Barbour April, Cavallari Larisa H, Perera Minoli |
|
Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
International journal of clinical pharmacology and therapeutics 2017 02 55 (2): 126-132. Chen Weirong, Wu Luhua, Liu Xin, Shen Yue, Liang Yan, Zhu Jun, Tan Huiqiong, Yang Yanmin, Liu Qun, Wang Mingsheng, Liu Lisheng, Wang Xing |
|
The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
Blood cells, molecules & diseases 2016 Dec . Nowak-Göttl U, Dietrich K, Kruempel A, Geisen C, Mitchell L |
|
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
Medicine 2016 Dec 95 (52): e5451. Misasi Silvia, Martini Giuliana, Paoletti Oriana, Calza Stefano, Scovoli Giovanni, Marengoni Alessandra, Testa Sophie, Caimi Luigi, Marchina Eleono |
|
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Thrombosis and haemostasis 2016 May 116 (2): . Whitlock Richard P, Whitlock Richard, Fordyce Christopher B, Midei Mark G, Ellis Dave, Garcia David, Weitz Jeffrey I, Canafax Daniel M, Albrecht Detlef, Milner Peter |
|
Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices†.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2016 Mar . Brehm Kerstin, Krumnau Oliver, Heilmann Claudia, Beyersdorf Friedhe |
|
[FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].
Georgian medical news 2016 Jan (250): 46-51. Jokhadze T, Kakauridze N, Buadze T, Gaiozishvili M, Lezhava |
|
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement.
Cellular and molecular biology (Noisy-le-Grand, France) 2016 62 (1): 51-5. Kirac D, Erdem A, Avcilar T, Yesilcimen K, Guney A I, Emre A, Yazici S, Terzi S, Kaspar E C, Cetin S E, Isbir |
|
High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Drug discoveries & therapeutics 2016 9 (6): 404-10. Sehgal Tushar, Hira Jasbir Kaur, Ahluwalia Jasmina, Das Reena, Vijayvergiya Rajesh, Rana Sandip Singh, Varma Neel |
|
Pharmacogenomic Testing and Warfarin Management.
Oncology nursing forum 2015 Sep 42 (5): 563-5. Maluso Andr |
|
Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery.
Journal of thrombosis and haemostasis : JTH 2015 Aug 13 (8): 1436-40. Abohelaika S, Wynne H, Avery P, Kamali |
|
Influence of UDP-glucuronosyltransferase polymorphisms on stable warfarin doses in patients with mechanical cardiac valves.
Cardiovascular therapeutics 2015 Jul . An Sook Hee, Chang Byung Chul, Lee Kyung Eun, Gwak Hye S |
|
Race influences warfarin dose changes associated with genetic factors.
Blood 2015 Jul 126 (4): 539-45. Limdi Nita A, Brown Todd M, Yan Qi, Thigpen Jonathan L, Shendre Aditi, Liu Nianjun, Hill Charles E, Arnett Donna K, Beasley T Ma |
|
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2015 Jun 98 (6): 549-54. Sermsathanasawadi Nuttawut, Sritongsathian Chukij, Pongrattanaman Nunthapol, Praditsuktavorn Banjerd, Hongku Kiattisak, Wongwanit Chumpol, Ruangsetakit Chanean, Chinsakchai Khamin, Mutirangura Pramook, Poungvarin Narav |
|
Genetic polymorphisms of ALOX5AP and CYP3A5 increase susceptibility to ischemic stroke and are associated with atherothrombotic events in stroke patients.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2015 Mar 24 (3): 521-9. Yi Xingyang, Zhang Biao, Wang Chun, Liao Duanxiu, Lin Jing, Chi Lif |
|
[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].
Kardiologiia 2015 55 (4): 57-60. Kokh N V, Slepukhina A A, Tsvetovskaya G A, Lifshits G |
|
[HAS-BLED and HEMORR2HAGES Scales in Assessment of Bleeding Risk in Patients on Long-Term Warfarin Therapy].
Kardiologiia 2015 55 (9): 50-6. Moreva O V, Kropacheva E S, Panchenko E P, Dobrovolsky A B, Zemlyanskaya O A, Donnikov A E, Titaeva E V, Guskova I |
|
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
Molecular diagnosis & therapy 2014 Dec 18 (6): 675-83. de Oliveira Almeida Vanessa Cristina, Ribeiro Daniel Dias, Gomes Karina Braga, Godard Ana Lúcia Brunial |
|
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.
Pharmacogenetics and genomics 2014 Oct 24 (10): 501-13. Jiménez-Varo Enrique, Cañadas-Garre Marisa, Gutiérrez-Pimentel María J, Calleja-Hernández Miguel |
|
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.
Journal of thrombosis and haemostasis : JTH 2014 Sep 12 (9): 1480-7. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci P |
|
Pharmacogenetics role in the safety of acenocoumarol therapy.
Thrombosis and haemostasis 2014 Sep 112 (3): 522-36. Jiménez-Varo E, Cañadas-Garre M, Henriques C I, Pinheiro A M, Gutiérrez-Pimentel M J, Calleja-Hernández M |
|
Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
Irish journal of medical science 2014 Jun 183 (2): 161-72. Bazan N S, Sabry N A, Rizk A, Mokhtar S, Badary O |
|
VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2014 Jun . Azzam Hanan, Elwakeel Hossam, Awad Ibrahim, El-Farahaty Reham, El-Gilany Abdel-Hady, El-Sharawy Sola |
|
Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
Thrombosis research 2014 May 133 (5): 729-35. De Tanima, Christopher Rita, Nagaraja Dindag |
|
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
European journal of clinical pharmacology 2014 Jan 70 (1): 47-56. Krishna Kumar Dhakchinamoorthi, Shewade Deepak Gopal, Loriot Marie-Anne, Beaune Philippe, Balachander Jayaraman, Sai Chandran B V, Adithan Chandrasekar |
|
High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9.
International journal of clinical and experimental pathology 2014 7 (5): 2558-64. Chen Chunxia, Li Siyue, Lu Xiaojun, Tan Bin, Huang Chunyan, Qin |
|
A randomized trial of genotype-guided dosing of warfarin.
The New England journal of medicine 2013 Dec 369 (24): 2294-303. Pirmohamed Munir, Burnside Girvan, Eriksson Niclas, Jorgensen Andrea L, Toh Cheng Hock, Nicholson Toby, Kesteven Patrick, Christersson Christina, Wahlström Bengt, Stafberg Christina, Zhang J Eunice, Leathart Julian B, Kohnke Hugo, Maitland-van der Zee Anke H, Williamson Paula R, Daly Ann K, Avery Peter, Kamali Farhad, Wadelius Mia, |
|
An acenocoumarol dose algorithm based on a South-Eastern European population.
European journal of clinical pharmacology 2013 Nov 69 (11): 1901-7. Pop Tudor Radu, Vesa ?tefan Cristian, Trifa Adrian Pavel, Cri?an Sorin, Buzoianu Anca Da |
|
Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Pharmacogenetics and genomics 2013 Nov 23 (11): 611-8. Wolkanin-Bartnik Jolanta, Pogorzelska Hanna, Szperl Ma?gorzata, Bartnik Aleksandra, Koziarek Jacek, Bilinska Zofia |
|
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
JACC. Cardiovascular interventions 2013 Nov 6 (11): 11. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, De Micco F, Latronico MV, Pagnotta P, Condorelli G |
|
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2013 Aug 44 (2): 309-14; discussion 314-5. Brehm Kerstin, Schack Jenny, Heilmann Claudia, Blanke Philipp, Geissler Hans Joachim, Beyersdorf Friedhe |
|
Does CALU SNP rs1043550 contribute variability to therapeutic warfarin dosing requirements?
Clinical medicine & research 2013 Jun 11 (2): 73-9. Glurich Ingrid, Berg Richard L, Burmester James |
|
Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
European journal of pharmacology 2013 Jun 710 (1-3): 80-4. Gaikwad Tejasvita, Ghosh Kanjaksha, Kulkarni Bipin, Kulkarni Vrinda, Ross Cecil, Shetty Shrima |
|
The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin.
Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina 2013 Feb 10 (1): 1. Ucar M, Alagozlu H, Sahin S, Ozdemir O |
|
Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial.
Trials 2012 Dec 13 (1): 1. Carcas AJ, Borobia AM, Velasco M, Abad-Santos F, Díaz MQ, Fernández-Capitán C, Ruiz-Giménez N, Madridano O, Sillero PL |
|
Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
The Journal of the Association of Physicians of India 2012 Dec 60 34-8. Shalia Kavita K, Doshi Shripal M, Parikh Suhas, Pawar Poonam P, Divekar Siddhi S, Varma Sandeep P, Mehta Rachna, Doctor Tasneem, Shah Vinod K, Saranath |
|
Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Pathologie-biologie 2012 Nov . Smires FZ, Habbal R, Moreau C, Assaidi A, Loriot MA, Nadifi S |
|
CYP2C9 and VKORC1 Gene Polymorphism is Inessential for Bleeding Development under Conditions of Oral Application of Anticoagulant Acenocoumarol in Russian Patients at High Risk of Thromboembolic Complications.
Bulletin of experimental biology and medicine 2012 Oct 153 (6): 6. Sychev DV, Ignatyev IV, Emelyanov NV, Milovanova VV, Kossovskaya AV, Kukes IV, Tashenova AI, Kukes VG |
|
Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
Journal of clinical pharmacy and therapeutics 2012 Oct 37 (5): 594-8. Smires F Z, Moreau C, Habbal R, Siguret V, Fadili S, Golmard J L, Assaidi A, Beaune P, Loriot M A, Nadifi |
|
The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.
Molecular biology reports 2012 Oct . Silan C, Dogan OT, Silan F, Kukulguven FM, Asgun HF, Ozdemir S, Uludag A, Atik S, Gungor B, Akdur S, Aksulu HE, Ozdemir O |
|
Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Journal of human genetics 2012 Oct 57 (10): 665-9. Pathare Anil, Al Khabori Murtadha, Alkindi Salam, Al Zadjali Shoaib, Misquith Rhea, Khan Hammad, Lapoumeroulie Claudine, Paldi Andras, Krishnamoorthy Rajagop |
|
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Thrombosis and haemostasis 2012 Jun 107 (6): 1083-91. Wei Meng, Ye Fei, Xie Dujiang, Zhu Yubing, Zhu Junrong, Tao Yifu, Yu Fe |
|
White blood cells contribute to patient-specific warfarin dose for Han Chinese.
Chinese medical journal 2012 Jun 125 (11): 1960-3. Zhu Jin, Zheng Wen-Jie, Zhang Wei-Juan, Wang He-Yao, Wang Ch |
|
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
Journal of thrombosis and haemostasis : JTH 2012 May 10 (5): 767-72. van Schie R M F, Babajeff A M V, Schalekamp T, Wessels J A M, le Cessie S, de Boer A, van der Meer F J M, van Meegen E, Verhoef T I, Rosendaal F R, Maitland-van der Zee A H, |
|
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
European journal of clinical pharmacology 2012 May 68 (5): 617-27. Mlynarsky Liat, Bejarano-Achache Idit, Muszkat Mordechai, Caraco Yose |
|
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention.
Thrombosis research 2012 Apr 129 (4): 441-6. Kassimis George, Davlouros Periklis, Xanthopoulou Ioanna, Stavrou Eleana F, Athanassiadou Aglaia, Alexopoulos Dimitri |
|
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Journal of thrombosis and haemostasis : JTH 2012 Apr 10 (4): 606-14. Verhoef T I, Redekop W K, Buikema M M, Schalekamp T, Van Der Meer F J M, Le Cessie S, Wessels J A M, Van Schie R M F, De Boer A, Teichert M, Visser L E, Maitland-Van Der Zee A H, |
|
Multivariate analysis of the relation between diet and warfarin dose.
European journal of clinical pharmacology 2012 Mar 68 (3): 321-8. Rasmussen Morten Arendt, Skov Jane, Bladbjerg Else-Marie, Sidelmann Johannes J, Vamosi Marianne, Jespersen Jørg |
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
Pharmacogenomics 2012 Feb 13 (3): 309-21. Zhang Wei, Zhang Wei-Juan, Zhu Jin, Kong Fan-Cui, Li Yan-Yan, Wang He-Yao, Yang Yuan-Hua, Wang Ch |
|
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.
PloS one 2012 7 (7): e41360. Borobia Alberto M, Lubomirov Rubin, Ramírez Elena, Lorenzo Alicia, Campos Armando, Muñoz-Romo Raul, Fernández-Capitán Carmen, Frías Jesús, Carcas Antonio |
|
Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Journal of clinical pharmacology 2011 Oct 51 (10): 1418-28. Esmerian Maria O, Mitri Zahi, Habbal Mohammad-Zuheir, Geryess Eddy, Zaatari Ghazi, Alam Samir, Skouri Hadi N, Mahfouz Rami A, Taher Ali, Zgheib Nathalie |
|
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome.
Thrombosis research 2011 Jun 127 (6): 595-9. Ames Paul R J, Margaglione Maurizio, Ciampa Antonio, Colaizzo Donatella, Ferrara Felicetto, Iannaccone Luigi, Vincenzobrancacci |
|
[CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications].
Vestnik Rossi?sko? akademii meditsinskikh nauk / Rossi?skaia akademiia meditsinskikh nauk 2011 (3): 3. Authors are not available |
|
CYP2C9 polymorphism studies in the Saudi population.
Saudi medical journal 2011 Apr 32 (4): 347-52. Saour Jalal N, Shereen Atia W, Saour Basil J, Mammo Layla |
|
Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
Journal of thrombosis and haemostasis : JTH 2011 Apr 9 (4): 711-8. Moreau C, Pautas E, Gouin-Thibault I, Golmard J-L, Mahé I, Mulot C, Loriot M-A, Siguret |
|
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Journal of thrombosis and haemostasis : JTH 2011 Jan 9 (1): 109-18. Watzka M, Geisen C, Bevans C G, Sittinger K, Spohn G, Rost S, Seifried E, Müller C R, Oldenburg |
|
[Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Terapevticheski? arkhiv 2011 83 (6): 59-65. Vorob'eva N M, Panchenko E P, Dobrovol'ski? A B, Titaeva E V, Khasanova Z B, Konovalova N V, Postnov A Iu, Kirienko A |
|
Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
BMC medical genetics 2011 12 80. Suriapranata Ivet M, Tjong Wen Ye, Wang Tingliang, Utama Andi, Raharjo Sunu B, Yuniadi Yoga, Tai Susan |
|
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease.
Annals of clinical and laboratory science 2011 41 (3): 229-35. Moon Hee-Won, Noh Jaekwang, Yun Yeo-Min, Kim Hahn Young, Yun Ik Jin, Song Junghan, Kim Jin |
|
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
European heart journal 2010 Dec 31 (24): 3046-53. Harmsze Ankie M, van Werkum Jochem W, Ten Berg Jurriën M, Zwart Bastiaan, Bouman Heleen J, Breet Nicoline J, van 't Hof Arnoud W J, Ruven Hendrik J T, Hackeng Christian M, Klungel Olaf H, de Boer Anthonius, Deneer Vera H |
|
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
Blood 2010 Dec 116 (26): 6101-5. Nowak-Göttl Ulrike, Dietrich Kevin, Schaffranek Daria, Eldin Noha Sharaf, Yasui Yutaka, Geisen Christof, Mitchell Lesley |
|
Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Thrombosis research 2010 Sep 126 (3): e235-7. Le Cam-Duchez Véronique, Frétigny Mathilde, Cailleux Nicole, Gandelin Catherine, Lévesque Hervé, Borg Jeanne-Yvon |
|
The association of protein S Tokushima-K196E with a risk of deep vein thrombosis.
International journal of hematology 2010 Sep 92 (2): 302-5. Ikejiri Makoto, Wada Hideo, Sakamoto Yuko, Ito Naohiko, Nishioka Junji, Nakatani Kaname, Tsuji Akihiro, Yamada Norikazu, Nakamura Mashio, Ito Masaaki, Nobori Tsuto |
|
[Association of polymorphisms of cytochrome P450 2C9 exon 4 and -65G>C with warfarin sensitivity].
Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2010 Aug 27 (4): 428-32. Wang Zan-xin, Huang Lei, Cai Heng, Men Jian-long, Wei Min-x |
|
VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis.
Thrombosis research 2010 Aug 126 (2): e134-6. Pasmant Eric, de Beauvoir Charlotte, Plessier Aurélie, Labreuche Julien, Bezeaud Ann |
|
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Thrombosis research 2010 Jun 125 (6): e259-64. Wells P S, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, Taljaard |
|
Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
Therapeutic drug monitoring 2010 Jun 32 (3): 338-45. McMillin Gwendolyn A, Melis Roberta, Wilson Andrew, Strong Michael B, Wanner Nathan A, Vinik Russell G, Peters Christopher L, Pendleton Robert |
|
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
Journal of the American College of Cardiology 2010 Jun 55 (25): 2804-12. Epstein Robert S, Moyer Thomas P, Aubert Ronald E, O Kane Dennis J, Xia Fang, Verbrugge Robert R, Gage Brian F, Teagarden J Russe |
|
Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2010 Feb 16 (1): 83-90. Palacio Lina, Falla Diana, Tobon Ignacio, Mejia Fernando, Lewis John E, Martinez Ariel F, Arcos-Burgos Mauricio, Camargo Mauric |
|
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.
Journal of thrombosis and haemostasis : JTH 2010 Jan 8 (1): 95-100. Ferder N S, Eby C S, Deych E, Harris J K, Ridker P M, Milligan P E, Goldhaber S Z, King C R, Giri T, McLeod H L, Glynn R J, Gage B |
|
[Anticoagulant action and safety of warfarin dosing based on pharmacogenetic testing: results of the first Russian prospective pilot study].
Kardiologiia 2010 50 (5): 42-6. Sychev D A, Antonov I M, Ignat'ev I V, Naumova Iu V, Dmitriev V A, Kropacheva E S, Dobrovol'ski? O B, Panchenko E P, Tashenova I A, Kukes V |
|
[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].
Terapevticheski? arkhiv 2010 82 (5): 33-9. Kondrat'eva L V, Patrusheva N L, Patrushev L I, Aleksandrova E N, Kovalenko T F, Ostriakova E V, Reshetniak T |
|
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
JACC. Cardiovascular interventions 2009 Nov 2 (11): 1095-101. Gladding Patrick, White Harvey, Voss Jamie, Ormiston John, Stewart Jim, Ruygrok Peter, Bvaldivia Badi, Baak Ruth, White Catherine, Webster Ma |
|
Perioperative genomic profiles using structure-specific oligonucleotide probes.
Clinical medicine & research 2009 Sep 7 (3): 69-84. Hogan Kirk J, Burmester James K, Caldwell Michael D, Hogan Quinn H, Coursin Douglas B, Green Dawn N, Selzer Rebecca M R, Broderick Thomas P, Rusy Deborah A, Poroli Mark, Lutz Anna L, Sanders Allison M, Oldenburg Mary C, Koelbl James A, de Arruda-Indig Monika, Halsey Jennifer L, Day Stephen P, Domanico Michael |
|
Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).
Thrombosis journal 2009 7 . Branco CC, Pereirinha T, Cabral R, Pacheco PR, Mota-Vieira L |
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
PLoS genetics 2009 Mar 5 (3): e1000433. Takeuchi Fumihiko, McGinnis Ralph, Bourgeois Stephane, Barnes Chris, Eriksson Niclas, Soranzo Nicole, Whittaker Pamela, Ranganath Venkatesh, Kumanduri Vasudev, McLaren William, Holm Lennart, Lindh Jonatan, Rane Anders, Wadelius Mia, Deloukas Pan |
|
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
Pharmacogenomics 2009 Feb 10 (2): 261-6. Borgiani Paola, Ciccacci Cinzia, Forte Vittorio, Sirianni Elisabetta, Novelli Lucia, Bramanti Placido, Novelli Giusep |
|
Cytochrome p-450 polymorphisms and response to clopidogrel.
The New England journal of medicine 2009 Jan 360 (4): 354-62. Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Hockett Richard D, Brandt John T, Walker Joseph R, Antman Elliott M, Macias William, Braunwald Eugene, Sabatine Marc |
|
VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
Pharmacogenomics 2008 Nov 9 (11): 1631-8. Markatos Christos N, Grouzi Elissavet, Politou Marianna, Gialeraki Argyri, Merkouri Efrosyni, Panagou Ioannis, Spiliotopoulou Ioanna, Travlou Ant |
|
Genetic factors contribute to patient-specific warfarin dose for Han Chinese.
Clinica chimica acta; international journal of clinical chemistry 2008 Oct 396 (1-2): 76-9. Wang Ting-Liang, Li Hong-Lei, Tjong Wen-Ye, Chen Qian-Su, Wu Guan-Sheng, Zhu Hai-Tao, Hou Zi-Shan, Xu Shu, Ma Sheng-Jun, Wu Madeline, Tai Sus |
|
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.
Journal of thrombosis and haemostasis : JTH 2008 Oct 6 (10): 1655-62. Lenzini P A, Grice G R, Milligan P E, Dowd M B, Subherwal S, Deych E, Eby C S, King C R, Porche-Sorbet R M, Murphy C V, Marchand R, Millican E A, Barrack R L, Clohisy J C, Kronquist K, Gatchel S K, Gage B |
|
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Clinical pharmacology and therapeutics 2008 Sep 84 (3): 326-31. Gage B F, Eby C, Johnson J A, Deych E, Rieder M J, Ridker P M, Milligan P E, Grice G, Lenzini P, Rettie A E, Aquilante C L, Grosso L, Marsh S, Langaee T, Farnett L E, Voora D, Veenstra D L, Glynn R J, Barrett A, McLeod H |
|
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Thrombosis and haemostasis 2008 Aug 100 (2): 229-39. Meckley Lisa M, Wittkowsky Ann K, Rieder Mark J, Rettie Allan E, Veenstra David |
|
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Pediatric blood & cancer 2008 Mar 50 (3): 710-3. Ruud Ellen, Holmstrøm Henrik, Bergan Stein, Wesenberg Fi |
|
[Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Kardiologiia 2008 48 (3): 52-7. Mikheeva Iu A, Kropacheva E S, Ignat'ev I V, Bulytova Iu M, Ramenskaia G V, Sychev D A, Dobrovol'ski? A B, Panchenko E |
|
Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Clinical pharmacokinetics 2008 47 (9): 565-94. Stehle Simone, Kirchheiner Julia, Lazar Andreas, Fuhr U |
|
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Pharmacogenomics 2007 Nov 8 (11): 1545-50. Borgiani Paola, Ciccacci Cinzia, Forte Vittorio, Romano Silvia, Federici Giorgio, Novelli Giusep |
|
Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Clinical biochemistry 2006 Jun 39 (6): 606-12. Moridani Majid, Fu Lei, Selby Rita, Yun Francisco, Sukovic Tatjana, Wong Betty, Cole David E |
|
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.
Journal of human genetics 2006 51 (3): 249-53. Mushiroda Taisei, Ohnishi Yozo, Saito Susumu, Takahashi Atsushi, Kikuchi Yuka, Saito Shigeru, Shimomura Hideki, Wanibuchi Yasuhiko, Suzuki Takao, Kamatani Naoyuki, Nakamura Yusu |
- Page last reviewed:Jul 30, 2019
- Page last updated:Aug 29, 2019
- Content source: